BRISTOL-MYER's PLATINOL EXCLUSIVE LICENSE EXTENDED UNTIL 1996
Executive Summary
BRISTOL-MYER's PLATINOL EXCLUSIVE LICENSE EXTENDED UNTIL 1996, when the government's patent on the compound expires, Bristol-Myers announced in a Jan. 15 release. The agreemment extends by eight years the company's right to exclusively market the anticancer agent. The recent extension of marketing exclusivity marks the second time Bristol-Myers has renegotiated its licensing agreement with the government. Under its initial licensing agreement, the company had rights to cisplatin through 1983. Bristol-Myers renegotiated the original agreement at the end of 1983 and obtained an additional five years of marketing exclusivity. Unlike the 1983 extension, there are no conditions to the most recent extension of the exclusive marketing rights, according to Bristol-Myers. As a condition of the 1983 licensing arrangement, Bristol-Myers agreed to conduct additional research and development work with the drug and to lower prices by 30%. Under the 1983 agreement, Bristol-Myers was to assess the use of Platinol in several new cancer indications, including: head and neck, cervical, prostate, malignant lymphoma, bone and soft tissue sarcoma, upper gastrointestinal, lung and esophageal. The company is in clinical trials with cisplatin for all of the additional indications except bone and soft tissue sarcoma, which is still being evaluated. Cisplatin is currently approved for use in bladder, testicular and ovarian cancers.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth